2023-505170-15-00招募中3 期
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease
Amicus Therapeutics Inc.14 个研究点 分布在 9 个国家目标入组 34 人开始时间: 2024年7月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 34
- 试验地点
- 14
- 主要终点
- Long-term safety: incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and AEs leading to discontinuation of study drug, frequency and severity of immediate and late IARs, and any abnormalities noted in other safety assessments (eg, clinical laboratory tests, ECGs, vital signs). Immunogenicity to ATB200 will also be described
研究概览
简要总结
Assess the long-term safety and tolerability of ATB200/AT2221 co-administration
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Subject must provide signed informed consent prior to any study- related procedures being performed. If the subject is under 20 years of age, the subject must provide written informed consent
- •Subject must have completed Study ATB200-
- •Note: Subjects who were forced to withdraw from Study ATB200-03 for a logistical reason not related to the efficacy or safety of ATB200/AT2221 (eg, hospitalization for a car accident, COVID-19 pandemic, or emergency surgery) and which resulted in several consecutive missed doses may be eligible to participate in this study upon approval by the Amicus medical monitor
- •Female subjects of childbearing potential and male subjects must agree to use medically accepted methods of contraception during the study and for 90 days after the last dose of study drug
排除标准
- •Subject plans to receive gene therapy or participate in another interventional study for Pompe disease
- •Subject has a hypersensitivity to any of the excipients in ATB200 or AT2221, or has a medical condition or any other extenuating circumstance that may, in the opinion of the investigator or medical monitor, pose an undue safety risk to the subject or may compromise his/her ability to comply with or adversely impact protocol requirements. This includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms
- •Subject, if female, is pregnant or breastfeeding
- •Subject, whether male or female, is planning to conceive a child during the study
结局指标
主要结局
Long-term safety: incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and AEs leading to discontinuation of study drug, frequency and severity of immediate and late IARs, and any abnormalities noted in other safety assessments (eg, clinical laboratory tests, ECGs, vital signs). Immunogenicity to ATB200 will also be described
Long-term safety: incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and AEs leading to discontinuation of study drug, frequency and severity of immediate and late IARs, and any abnormalities noted in other safety assessments (eg, clinical laboratory tests, ECGs, vital signs). Immunogenicity to ATB200 will also be described
次要结局
- Change from baseline in 6-minute walk distance (6MWD)
- Change from baseline in 6MWD (% predicted)
- Change from baseline in sitting FVC (% predicted)
- Change from baseline in the manual muscle test score for the lower extremities
- Change from baseline in the total score for the PROMIS – physical function
- Change from baseline in the total score for the PROMIS – fatigue
- Change from baseline in the following variables related to motor function: - GSGC total score, - time to complete the 10-meter walk (ie, assessment of gait) of the GSGC test, - time to complete the 4-stair climb of the GSGC test, - time to complete the Gower's maneuver of the GSGC test, - time to arise from a chair as part of the GSGC test, - change from baseline in the time to complete the TUG test
- Change from baseline in the following variables related to muscle strength: - manual muscle test score for the upper extremities, - manual muscle test total score (upper and lower extremities combined), - quantitative muscle test value (kg) for the upper extremities, - quantitative muscle test value (kg) for the lower extremities, - quantitative muscle test total value (kg) (upper and lower extremities combined)
- Change from baseline in the following variables from patient-reported outcome measures: - total score for the PROMIS-dyspnea, - total score for the PROMIS–upper extremity, - R-PAct Scale total score, - EQ-5D-5L health status
- Actual value of the subject's functional status (improving, stable, or declining) pertaining to the effects of study drug in the following areas of life, as measured by the SGIC: - overall physical well-being, - effort of breathing, - muscle strength, - muscle function, - ability to move around, - activities of daily living, - energy level, - level of muscular pain
- Actual value of the subject's functional status (improving, stable, or declining), as measured by the PGIC
- Change from baseline in the following measures of pulmonary function, as follows: - sitting SVC (% predicted), - MIP (cmH2O), - MIP (% predicted), - MEP (cmH2O), - MEP (% predicted), - SNIP (cmH2O)
- Change from baseline in serum CK level
- Change from baseline in urinary Hex4 level
研究者
Amicus Patient Advocacy
Scientific
Amicus Therapeutics Inc.
研究点 (14)
Loading locations...
相似试验
招募中
2 期
Safety and preliminary effectiveness of BNT327, an investigational therapy for patients with non-small cell lung cancer in combination with chemotherapy following chemoimmunotherapyNon-small Cell Lung Cancer2024-518279-80-00BioNTech SE10
招募中
2 期
A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not Responsive After Treatment or Who Had Myeloma Which Has Returned After a Period of Treatment2023-508727-12-00Celgene Corp.46
已完成
2 期
A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific mutations that occur in all cancer cells within a single patientNon-small cell lung cancer2024-513060-26-00Achilles Therapeutics UK Limited24
招募中
2 期
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialGlioblastomaNCT07263438Centre Hospitalier Universitaire Vaudois59
招募中
1 期
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsNSCLCNCT07274813Shanghai Henlius Biotech254